Why the study?
Do isradipine and other new antihypertensive agents improve the management of peri- and postoperative hypertension compared to traditional therapy like sodium nitroprusside?
Do isradipine and other new antihypertensive agents improve the management of peri- and postoperative hypertension compared to traditional therapy like sodium nitroprusside?
Answers are grounded in this paper and cite their sources.
Dihydropyridine calcium antagonists, particularly isradipine, offer a practical advantage over sodium nitroprusside in managing perioperative hypertension by allowing bolus dosing for transient blood pressure elevations.
The traditional therapy of perioperative hypertension is now being challenged by the availability of new agents. Vasodilator therapy should be the first-line choice, although dihydropyridine calcium antagonists, particularly isradipine, appear to be suitable in this setting because of their pharmacological properties. Because of its ultrashort half-life, sodium nitroprusside has to be administered by continuous infusion, even for the treatment of an acute elevation of blood pressure. This is not the case with the new agents that have longer durations of action. A bolus administration is sufficient for the correction of most elevations of arterial pressure that are due to transient adrenergic activation. Continuous infusion is required only in patients who have sustained increases of systemic vascular resistance; these are usually patients who are already hypertensive.
No takes yet. Share an insight, caveat, or question.
J. Marty (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: